Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 11/20 | 0.49 |
| ▸ | CLK3 | P49761 | 11/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.49 |
| ▸ | WNT1 | P04628 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 3/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18443331 | 0.91 | CLK2 (0.61) | CLK2CLK3DYRK1AWNT1MAP4K1 | |
| SCHEMBL18451035 | 0.90 | CLK2 (0.56) | CLK2CLK3DYRK1AWNT1CDK9 | |
| SCHEMBL18445131 | 0.89 | WNT1 (0.50) | CLK2CLK3DYRK1AWNT1CDK9 | |
| SCHEMBL18448944 | 0.88 | CDK9 (0.61) | CLK2CLK3DYRK1AWNT1CDK9 | |
| SCHEMBL18445815 | 0.88 | WNT1 (0.59) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL20775498 | 0.87 | CLK2 (0.54) | CLK2CLK3DYRK1AWNT1CDK9 | |
| SCHEMBL18445430 | 0.86 | WNT1 (0.45) | CLK2CLK3DYRK1AWNT1CDK9 | |
| SCHEMBL18445415 | 0.86 | CLK2 (0.49) | CLK2CLK3DYRK1AWNT1MAP4K1 | |
| SCHEMBL18445106 | 0.85 | CLK2 (0.49) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL18445735 | 0.84 | CLK2 (0.48) | CLK2CLK3DYRK1AWNT1ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226453-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-03-12 | — | — | US | claimed |
| WO-2017023993-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| US-10226453-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226453-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | CLK2 1586/4885CLK3 1498/4885DYRK1A 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.